Changing the diagnosis of acute myocardial infarction: Implications for practice and clinical investigations☆☆☆★★★
To access this article, please choose from the options below
☆ Supported by unrestricted educational grants from: Aventis Pharmaceuticals, Abbott Diagnostic, COR Therapeutics, Inc., First Medical, The Medicines Company, Merck & Co., Pfizer Inc., Proctor & Gamble Pharmaceuticals, Roche Diagnostics Corporation, Schering-Plough Research Institute, Wyeth-Ayerst Research
☆☆ Reprint requests: L. Kristin Newby, MD, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715-7969.
★ E-mail: newby001@mc.duke.edu
★★ *A complete list of participants is listed in the Appendix.
PII: S0002-8703(02)00220-X
doi:10.1067/mhj.2002.129778
© 2002 Published by Elsevier Inc.
Refers to article:
- Things ain't what they used to be: Impact of a new definition of myocardial infarction
- European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: How to use existing assays clinically and for clinical trials
